Evidence map›Paper›PMID 28722755›Full record

ReviewAllergy2018

The potential of anti-infectives and immunomodulators as therapies for asthma and asthma exacerbations.

M R Edwards, R P Walton, D J Jackson, W Feleszko, C Skevaki, T Jartti, H Makrinoti, A Nikonova, I P Shilovskiy, J Schwarze and 3 more

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Allergy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 2 pooled it
10.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 57 citations in OpenAlex.

  1. Pooled it
  2. Bacterial lysate therapy for the prevention of wheezing episodes and asthma exacerbations: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2020
    Pooled it
  3. Bacterial lysate add-on therapy to reduce exacerbations in severe asthma: A double-blind placebo-controlled trial.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2021
    Trial
  4. Trial
  5. Review
  6. Article
  7. Targeting respiratory virus-induced reactive oxygen species in airways diseases.European respiratory review : an official journal of the European Respiratory Society · 2025
    Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 6 countries.

M R EdwardsAirway Disease Infection Section, National Heart Lung Institute, Imperial College London, London, UK.
R P WaltonAirway Disease Infection Section, National Heart Lung Institute, Imperial College London, London, UK.
D J JacksonAirway Disease Infection Section, National Heart Lung Institute, Imperial College London, London, UK.
W FeleszkoDepartment of Pediatric Respiratory Diseases and Allergy, The Medical University of Warsaw, Warsaw, Poland.
C SkevakiInstitute of Laboratory Medicine and Pathobiochemistry, Molecular Diagnostics, Philipps University Marburg & University Hospital Giessen, Marburg, Germany.
T JarttiThe Department of Pediatrics, Turku University Hospital, Turku, Finland.
H MakrinotiAirway Disease Infection Section, National Heart Lung Institute, Imperial College London, London, UK.
A NikonovaNational Research Center Institute of Immunology of Federal Medicobiological Agency, Moscow, Russia.
I P ShilovskiyNational Research Center Institute of Immunology of Federal Medicobiological Agency, Moscow, Russia.
J SchwarzeCentre for Inflammation Research, University of Edinburgh, The Queens Medical Research Institute Edinburgh, Edinburgh, UK.
S L JohnstonAirway Disease Infection Section, National Heart Lung Institute, Imperial College London, London, UK.
M R KhaitovNational Research Center Institute of Immunology of Federal Medicobiological Agency, Moscow, Russia.ORCID http://orcid.org/0000-0003-4961-9640
EAACI Anti-infectives in Asthma and Asthma Exacerbations Task Force
Lung Institute · USFederal Medical-Biological Agency · RUCentre for Inflammation Research · GBKing's College London · GBMedical University of Warsaw · PLResearch Institute of Vaccines and Sera. Mechnikov of the Russian Academy of Medical Sciences · RUTurku University Hospital · FIUniversitätsklinikum Gießen und Marburg · DE

Funding

Medical Research Council G1000758
6 · The paper itself

Abstract

Asthma is responsible for approximately 25,000 deaths annually in Europe despite available medicines that maintain asthma control and reduce asthma exacerbations. Better treatments are urgently needed for the control of chronic asthma and reduction in asthma exacerbations, the major cause of asthma mortality. Much research spanning >20 years shows a strong association between microorganisms including pathogens in asthma onset, severity and exacerbation, yet with the exception of antibiotics, few treatments are available that specifically target the offending pathogens. Recent insights into the microbiome suggest that modulating commensal organisms within the gut or lung may also be a possible way to treat/prevent asthma. The European Academy of Allergy & Clinical Immunology Task Force on Anti-infectives in Asthma was initiated to investigate the potential of anti-infectives and immunomodulators in asthma. This review provides a concise summary of the current literature and aimed to identify and address key questions that concern the use of anti-infectives and both microbe- and host-based immunomodulators and their feasibility for use in asthma.

Indexed as

Age FactorsAnti-Asthmatic AgentsAnti-Infective AgentsAsthmaDisease ProgressionFemaleHumansImmunologic FactorsImmunomodulationMalePregnancyPregnancy ComplicationsProbioticsTreatment OutcomeVaccinesAnti-Asthmatic AgentsAnti-Infective AgentsImmunologic FactorsVaccinesanti-infectiveAsthmaimmunomodulatorinfectionlung

Identifiers

PMID28722755
PMCPMC7159495
OpenAlexW2739294496

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.